The European Society for Medical Oncology Gastrointestinal Cancers Annual Congress 2024 (ESMO GI 2024)

Munich, Germany 26 June 2024 - 29 June 2024

NALIRIFOX improves survival in older patients with mPDAC

31 Aug 2024 bởi

Treatment with liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX) improved overall survival (OS) and progression-free survival (PFS) in patients aged ≥65 years with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP), according to a post hoc analysis of the phase III NAPOLI 3 trial presented at ESMO GI 2024.

31 Aug 2024

AI helps spot HCC sooner

23 Aug 2024 bởi

A novel artificial intelligence (AI) classifier can detect hepatocellular carcinoma (HCC) signatures in routine blood tests up to 1 year before clinical diagnosis, as shown in a study from Hong Kong.

23 Aug 2024

Neoadjuvant regorafenib, nivolumab, SCRT combination looks good for rectal cancer

22 Aug 2024 bởi

Treatment with the combination of regorafenib, nivolumab, and short-course radiotherapy (SCRT) in the neoadjuvant setting has induced response in stage II-III rectal adenocarcinoma in the phase II REGINA trial, meeting the predefined statistical criteria.

22 Aug 2024

Chemo plus liver transplant prolongs survival in unresectable colorectal liver metastases

13 Aug 2024 bởi

Liver transplantation (LT) in combination with chemotherapy, as opposed to chemotherapy alone, can provide a meaningful improvement in survival among patients with unresectable colorectal liver metastases, suggest the results of the TRANSMET trial presented at ESMO GI 2024.

13 Aug 2024

First-line nivolumab-ipilimumab improves life quality, eases symptoms in metastatic CRC

12 Aug 2024 bởi

First-line treatment with nivolumab (NIVO) in combination with ipilimumab (IPI) results in better health-related quality of life (HRQOL) and fewer symptoms, when compared with chemotherapy, in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), as shown in the CheckMate 8HW study presented at ESMO GI 2024.

12 Aug 2024

KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer

05 Aug 2024 bởi

Perioperative pembrolizumab plus chemotherapy confers survival benefit in individuals with locally advanced gastric and gastroesophageal junction (G/GEJ) cancer in the final analysis of the phase III KEYNOTE-585 trial.

05 Aug 2024

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

31 Jul 2024 bởi

In the 3-year updated analysis of the phase III TOPAZ-1 study, the combination of durvalumab and gemcitabine-cisplatin (GC) chemotherapy continues to deliver an overall survival (OS) benefit in individuals with biliary tract cancer (BTC).

31 Jul 2024